josephfoss
- Jul 6, 2020
- 1 min read

NeuroTherapia completes enrollment in Phase 1 first-in-human trial of NTRX-07

NeuroTherapia has completed enrollment of its Phase 1 single dose study of NTRX-07 in normal volunteers. Top line data is expected to be presented at the AAIC virtual meeting in July.

The study is designed to provide initial safety data and human pharmacokinetics of NTRX-07 in preparation for planned upcoming trials in patients.

Recent Posts

See All

NeuroTherapia Initiates First-In-Human Clinical Trials of NTRX-07 For Alzheimer’s Disease

NeuroTherapia, Inc., a Cleveland Clinic spin-off company, has started its first-in-human Phase I clinical trial of NTRX-07, a new drug targeting the inflammation in the brain that is found in Alzheime

NeuroTherapia to Start Clinical Trials of NTRX-07 For Alzheimer’s Disease

CLEVELAND, OH – NeuroTherapia, Inc., a Cleveland Clinic spin-off company, will be starting clinical trials of NTRX-07, a new drug targeting inflammation in the brain that is found in Alzheimer’s disea

Alzheimer's Association Supports First Human Trials of NTRX-07

NeuroTherapia has received funding from the Alzheimer's Association to support the first human trials of NTRX-07, a novel new therapy targeted towards inflammation in the brain and nervous system. The